Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...
查看详情CHMP positive opinion is based on a robustanalytical, non-clinical and clinical data package comparing Avzivi® to theref...
Guangzhou, China– June 2 , 2024 –Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydevel...
Bio-Theraand STADA have reached an exclusive commercialization and license agreement forBAT2506, a biosimilar candidate...